 |
||||
| 2007 JASN IMPACT FACTOR 7.111 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
|
||||
| 2007 JASN IMPACT FACTOR 7.111 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
*Division of Pediatric Nephrology, University Children’s Hospital, Heidelberg, Germany; Department of Clinical Chemistry, Georg-August University, Göttingen, Germany; and University Children’s Hospital Freiburg, Germany.
Correspondence to: Dr. Burkhard Tönshoff, Division of Pediatric Nephrology, University Children’s Hospital, Im Neuenheimer Feld 150, 69120 Heidelberg, Germany. Phone: 49-6221-562311; Fax: 49-6221-564203; E-mail: Burkhard_Toenshoff{at}med.uni-heidelberg.de
ABSTRACT. It is currently being debated whether pharmacokinetic monitoring of mycophenolic acid (MPA), the active constituent of mycophenolate mofetil (MMF), can optimize MMF therapy after organ transplantation. This open-label longitudinal study in pediatric renal transplant recipients was designed to investigate the pharmacokinetic (PK)/pharmacodynamic relationship of total and free MPA and to establish PK values for the assessment of an individual’s MPA PK parameters. Fifty-four children, aged 2.2 to 17.8 yr, on an immunosuppressive triple regimen consisting of cyclosporin A, prednisone, and MMF (600 mg/m2 body surface area twice daily) were investigated 1 wk and 3 wk (initial phase) and 3 mo and 6 mo (stable phase) after renal transplantation. MPA was measured by reverse phase HPLC, free MPA by HPLC after separation by ultrafiltration. There was an association between the risk of acute rejection episodes and MPA-AUC0-12 values or MPA predose levels; by receiver operating characteristic analysis, an AUC0-12 of 33.8 mg x h/L in the initial phase posttransplant had a diagnostic sensitivity of 75% and a diagnostic specificity of 64% for discrimination of patients with acute rejections. The respective discrimination threshold for the MPA predose concentration was 1.2 mg/L with a sensitivity of 83% and a specificity of 64%. In contrast, high free, but not total, MPA-AUC0-12 values were associated with an increased risk of the MMF-related side effects leukopenia and/or infections. These data indicate that therapeutic drug monitoring of MPA has the potential for optimization of MMF efficacy in this patient population by steering patients away from the low values of MPA PK variables that are associated with an increased rejection risk. For the assessment of the toxic risk of MMF regarding leukopenia and/or infections, measurement of free MPA appears to be more appropriate.
This article has been cited by other articles:
 |
|
 |
|
  R. Hanvesakul, C. Kubal, S. Jham, E. Sarkar, K. Eardley, D. Adu, and P. Cockwell Increased incidence of infections following the late introduction of mycophenolate mofetil in renal transplant recipients Nephrol. Dial. Transplant., December 1, 2008; 23(12): 4049 - 4053. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Jacobson, J. Huang, N. Rydholm, M. Tran, T. DeFor, J. Tolar, and P. J. Orchard Higher Mycophenolate Dose Requirements in Children Undergoing Hematopoietic Cell Transplant (HCT) J. Clin. Pharmacol., April 1, 2008; 48(4): 485 - 494. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.-P. Yau, A. Vathsala, H.-X. Lou, and E. Chan Is a standard fixed dose of mycophenolate mofetil ideal for all patients? Nephrol. Dial. Transplant., December 1, 2007; 22(12): 3638 - 3645. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Shaw, M. Figurski, M. C. Milone, J. Trofe, and R. D. Bloom Therapeutic Drug Monitoring of Mycophenolic Acid Clin. J. Am. Soc. Nephrol., September 1, 2007; 2(5): 1062 - 1072. [Full Text] [PDF]
|
|
|
|
|
|
H. Jeong and B. Kaplan Therapeutic Monitoring of Mycophenolate Mofetil Clin. J. Am. Soc. Nephrol., January 1, 2007; 2(1): 184 - 191. [Full Text] [PDF]
|
|
|
|
 |
|
 O. Bernard, J. Tojcic, K. Journault, L. Perusse, and C. Guillemette Influence of Nonsynonymous Polymorphisms of UGT1A8 and UGT2B7 Metabolizing Enzymes on the Formation of Phenolic and Acyl Glucuronides of Mycophenolic Acid Drug Metab. Dispos., September 1, 2006; 34(9): 1539 - 1545. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. van Hest, R. A.A. Mathot, M. D. Pescovitz, R. Gordon, R. D. Mamelok, and T. van Gelder Explaining Variability in Mycophenolic Acid Exposure to Optimize Mycophenolate Mofetil Dosing: A Population Pharmacokinetic Meta-Analysis of Mycophenolic Acid in Renal Transplant Recipients J. Am. Soc. Nephrol., March 1, 2006; 17(3): 871 - 880. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Giaccone, J. S. McCune, M. B. Maris, T. A. Gooley, B. M. Sandmaier, J. T. Slattery, S. Cole, R. A. Nash, R. F. Storb, and G. E. Georges Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation Blood, December 15, 2005; 106(13): 4381 - 4388. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Jacobson, K. G. Green, and B. J. Hering Mycophenolate Mofetil in Islet Cell Transplant: Variable Pharmacokinetics but Good Correlation Between Total and Unbound Concentrations J. Clin. Pharmacol., August 1, 2005; 45(8): 901 - 909. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Hazzan, M. Labalette, M. C. Copin, F. Glowacki, F. Provot, F.-R. Pruv, and C. Noel Predictive Factors of Acute Rejection after Early Cyclosporine Withdrawal in Renal Transplant Recipients Who Receive Mycophenolate Mofetil: Results from a Prospective, Randomized Trial J. Am. Soc. Nephrol., August 1, 2005; 16(8): 2509 - 2516. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. M. Annesley and L. T. Clayton Quantification of Mycophenolic Acid and Glucuronide Metabolite in Human Serum by HPLC-Tandem Mass Spectrometry Clin. Chem., May 1, 2005; 51(5): 872 - 877. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. G Morris Immunosuppressant Drug Monitoring: Is the Laboratory Meeting Clinical Expectations? Ann. Pharmacother., January 1, 2005; 39(1): 119 - 127. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Streit, M. Shipkova, V. W. Armstrong, and M. Oellerich Validation of a Rapid and Sensitive Liquid Chromatography-Tandem Mass Spectrometry Method for Free and Total Mycophenolic Acid Clin. Chem., January 1, 2004; 50(1): 152 - 159. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Neumann, M. Haidinger, H. Jager, H. Grutzmacher, A. Griesmacher, M. M. Muller, P. M. Bayer, and F. Thomas Meisl Pharmacokinetics of Mycophenolate Mofetil in Patients with Autoimmune Diseases Compared Renal Transplant Recipients J. Am. Soc. Nephrol., March 1, 2003; 14(3): 721 - 727. [Abstract] [Full Text] [PDF]
|
|
|
HOME
CURRENT ISSUE
ARCHIVES
JASN Express
ONLINE SUBMISSION
AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP |
Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673
